Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group I: Investigational MenABCWY Formulation 1 | EXPERIMENTAL | - |
| Group II: Investigational MenABCWY Formulation 2 | EXPERIMENTAL | - |
| Group III: Investigational MenABCWY Formulation 3 | EXPERIMENTAL | - |
| Group IV: Investigational MenABCWY Formulation 4 | EXPERIMENTAL | - |
| Group V: Active comparator investigational MenB | ACTIVE_COMPARATOR | - |
| Group VI: Active comparator MenACWY | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Meningococcal Vaccine | BIOLOGICAL | MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months. |
Inclusion Criteria: Individuals eligible to be enrolled into this study are male and female subjects: 1. 11-18 years at the time of enrollment; 2. who have given their written consent/assent and whose parents or legal guardians have given written informed consent at the time of enrollment; 3. who ...
It is an investigational vaccine developed by Novartis AG for the prevention of meningococcal disease, including meningococcal meningitis. It is a vaccine modality in Phase 2 clinical development. The program has been studied in adolescents, a population at risk for meningococcal infection.
The Meningococcal Vaccine is being developed for meningococcal disease and meningococcal meningitis. Its Phase 2 trial enrolled healthy adolescent volunteers aged 11 years and older in Chile, Colombia, and Panama. It is an investigational product and is not described as approved for use.
Novartis AG, which trades under the ticker NVS, is the developer of this Meningococcal Vaccine. The company sponsored the Phase 2 study evaluating different rMenB plus MenACWY formulations in adolescents.
The Meningococcal Vaccine is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The completed study was randomized and active controlled, with 495 participants enrolled.
The Meningococcal Vaccine has been evaluated in one completed Phase 2 trial, NCT01210885, titled Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents. It enrolled 495 healthy volunteers aged 11 years and older across Chile, Colombia, and Panama and used an active-controlled, randomized design.